NCT01295060View on ClinicalTrials.gov

Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly

PHASE3TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

June 30, 2012

Conditions
Acromegaly
Interventions
DRUG

Octreotide

84 mg Octreotide Implant

Trial Locations (6)

21215

Baltimore

44195

Cleveland

60611

Chicago

80220

Denver

97239

Portland

98122

Seattle

Sponsors
All Listed Sponsors
lead

Endo Pharmaceuticals

INDUSTRY